Ab­b­Vie scores speedy re­view for RA drug upadac­i­tinib; Mer­ck KGaA wins CRISPR patent

→ Ab­b­Vie $AB­BV has high hopes, pro­ject­ing peak po­ten­tial sales of $6.5 bil­lion, for its oral JAK1 in­hibitor upadac­i­tinib for rheuma­toid arthri­tis, which is up against well-en­trenched ri­vals. On Tues­day, the drug­mak­er said FDA had re­ward­ed the drug — which is al­so un­der EU re­view — pri­or­i­ty re­view, and that the US health reg­u­la­tor is ex­pect­ed to makes its de­ci­sion by the third quar­ter of 2019.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN